First global data, from Rosetta Lung-02 in first-line NSCLC, tell a familiar story.
ApexOnco Front Page
Recent articles
Silevertinib efficacy comes close to firmonertinib’s, but toxicity is a new worry.
New data with pasritamig plus docetaxel support a recent pivotal start.
Decisions and readouts loom for the SERDs Astra’s camizestrant and Roche’s giredestrant.
An FDA verdict is due in the third quarter, as Protagonist looks likely to opt out.
The first fruit of a long-standing deal with Roche enters phase 1 in March.
But biomarker enrichment and toxicity remain key for FX-909.
The month saw the first commissioner's priority voucher approval in oncology.
